Related by context. All words. (Click for frequent words.) 76 Disease Activity 75 DAS# CRP 74 Crohn Disease Activity 72 CDAI 72 Expanded Disability Status 71 Index CDAI 70 HAQ DI 70 NIHSS 70 NIH CPSI 69 Psoriasis Area 69 CDAI score 69 EDSS score 68 Score DAS# 68 IPSS 67 Severity Index PASI 67 PANSS 67 Montgomery Asberg Depression 67 ACR# [002] 67 SELENA SLEDAI 67 Score DAS 67 Scale EDSS 67 MADRS score 66 Unified Parkinson Disease 66 Health Assessment Questionnaire 66 apnea hypopnea index 66 PANSS total 66 CCyR 66 EDSS 66 Rating Scale MADRS 66 Index CDAI score 66 mTSS 66 HDRS 65 Brief Psychiatric 65 IRLS score 65 Montgomery Åsberg Depression 65 Alzheimer Disease Assessment 65 YMRS 65 erythrocyte sedimentation rate 65 baseline HbA1c 65 HbA 1c levels 65 DAS# remission 65 Hb A1C 65 Negative Syndrome 65 alanine aminotransferase ALT 65 UPDRS 65 % CI #.#-#.# [007] 65 BMI z 65 symptom severity 65 Visual Analogue Scale VAS 64 DAS# scores 64 ACR# response 64 MetS 64 MADRS 64 PSADT 64 SGRQ 64 Response Evaluation Criteria 64 preoperatively 64 P = .# 64 HOMA IR 64 International Prostate Symptom 64 achieved ACR# 64 ACR Pedi 64 hemoglobin A1c levels 64 lopinavir r arm 64 glycated hemoglobin levels 63 serum urate 63 ADAS cog 63 serologically active patients 63 alanine aminotransferase 63 log# copies mL 63 p = #.# [002] 63 definite stent thrombosis 63 plus methotrexate 63 HBeAg seroconversion 63 WOMAC 63 estimated glomerular filtration 63 QoL 63 Visual Analog Scale 63 ADCS CGIC 63 lumbar spine BMD 63 Scale EDSS score 63 Rating Scale BPRS 63 IBDQ 62 albumin excretion rate 62 RECIST Response Evaluation Criteria 62 MMSE scores 62 intima media thickness 62 APACHE II 62 sd = 62 Rating Scale UPDRS 62 mmol l 62 HbA 1c 62 clinically meaningful improvement 62 Score TOS 62 % CI #.#-#.# [008] 62 fasting insulin 62 macroalbuminuria 62 antibody titer 62 fasting plasma glucose 62 Score IPSS 62 creatinine clearance 62 NYHA functional class 62 glycated hemoglobin 62 Ishak fibrosis score 62 nasal symptom 62 hip BMD 62 radiographic progression 62 methotrexate monotherapy 62 #.#ng/ml 62 HAMD 62 liver histology 62 sUA 62 glomerular filtration rate 62 ADAS Cog 62 WOMAC pain 62 PASI scores 62 oxycodone CR 62 SELENA SLEDAI score 61 lowest tertile 61 QIDS SR 61 univariate analysis 61 endometrial thickness 61 serum testosterone 61 % Confidence Interval 61 UPDRS motor 61 placebo p = 61 PSA nadir 61 mRS 61 CNS LS 61 RECIST criteria 61 Ejection Fraction 61 Solid Tumors criteria 61 subscale scores 61 subscales 61 Primary endpoints 61 FOLPI 61 highest tertile 61 Y BOCS 61 serum HBV DNA 61 HRQoL 61 annualized relapse 61 baseline A1C 61 x ULN 61 femoral neck BMD 61 MMSE score 61 elevated ALT 61 MMSE 61 logistic regression analysis 61 -#.# log# 61 mL/min/#.# m 2 61 biochemical recurrence 61 ACR# responses 61 cTnT levels 61 Secondary endpoints 61 Severity MSCS score 61 Solid Tumors RECIST 61 pCR 61 CI -#.# 61 biopsy Gleason 61 tipranavir r 61 % CI #.#-#.# [003] 61 IU mL 61 Pain Intensity 61 OGTT 61 systolic dysfunction 61 p = .# [002] 61 IRLS 60 Fibromyalgia Impact Questionnaire 60 binary restenosis 60 enthesitis 60 Scale cognitive subscale 60 % CI #.#-#.# [006] 60 HbA1c levels 60 #mg/day [001] 60 endoscopic remission 60 HRQL 60 confidence interval CI 60 Skin sterol 60 virologic response 60 CrCl 60 A1c levels 60 glycosylated hemoglobin HbA1c 60 p = .# [001] 60 timepoints 60 EDSS scores 60 rheumatoid factor 60 subscore 60 NIS LL 60 biochemical relapse 60 microalbuminuria 60 nondiabetic patients 60 complete cytogenetic 60 PCWP 60 abdominal pain abdominal discomfort 60 hemoglobin A1C 60 QTcF 60 mean baseline A1C 60 HAM D 60 eGFR 60 mg TID 60 subscores 60 Secondary efficacy endpoints 60 BILAG 60 mcg QD 60 platelet reactivity 60 aspartate aminotransferase 60 pT3 60 urine albumin 60 response CCyR 60 hemoglobin A1c HbA1c 60 creatinine ratio 60 XIENCE V PROMUS Stent 60 glycated hemoglobin HbA1c 60 MACCE 60 -#.# mg dL [002] 60 sustained virologic response 60 WOMAC scores 60 Scale PANSS 60 Knodell necroinflammatory score 59 HAM D# 59 aminotransferase elevations greater 59 URTI 59 HbA1C 59 serum potassium 59 multivariate analyzes 59 baseline LDH 59 carotid intima media 59 LVEF 59 leukocyte count 59 mg QD 59 mmHg diastolic 59 RECIST 59 nonsignificant 59 HbA1C levels 59 morphometric vertebral fractures 59 REYATAZ r arm 59 CIMZIA TM 59 estimated GFR 59 ACTEMRA TM 59 partial remissions 59 Scale Cognitive Subscale 59 dactylitis 59 mg BID 59 secondary endpoint 59 WOMAC TM 59 preoperative PSA 59 recurrent VTE 59 % CI #.#-#.# [004] 59 log# reduction 59 serum creatinine levels 59 colorectal adenoma 59 serum PSA 59 urinary albumin 59 budesonide pMDI 59 placebo p 59 TAXUS p value 59 oral glucose tolerance 59 tertile 59 nausea photophobia 59 corticosteroid dose 59 mIU L 59 refractory ischemia 59 ≥ 59 #.#/#.# mmHg [001] 59 adenoma recurrence 59 CR nPR 59 mcg BID 59 univariate 59 HBeAg negative 59 sustained virological response 59 MCyR 59 ACR# ACR# 59 confidence intervals CIs 59 nonfatal MI 59 lymphocyte count 59 A1C levels 59 serum thyroglobulin 59 spontaneous bowel movements 59 pain subscale 59 HbA1c 59 CI #.#-#.# [001] 59 depressive symptom 59 point Likert scale 59 peginterferon alfa 2a 59 Timed Walk 59 cytogenetic response 59 proteinuria 59 fasting triglyceride levels 59 hours postdose 59 glomerular filtration 59 carotid IMT 59 baseline PASI 59 dyspnoea 59 p = 59 #mg BID [001] 59 specific antigen PSA 59 extrapyramidal symptoms 59 diabetes mellitus DM 59 troponin T 58 nonfasting triglyceride levels 58 State Examination MMSE 58 odds ratios ORs 58 aspartate aminotransferase AST 58 ng dL 58 systemic embolism 58 serum phosphate 58 airflow obstruction 58 achieved statistical significance 58 complete cytogenetic response 58 symptomatic VTE 58 -#.# ± [002] 58 Partial Response 58 CI #.#-#.# [002] 58 seropositive patients 58 moderate renal impairment 58 T2DM 58 confidence interval #.#-#.# 58 log# 58 mucosal healing 58 mg BID dose 58 placebo fluoxetine 58 secondary efficacy endpoint 58 CSBMs 58 atheroma volume 58 amoxicillin clavulanate 58 timepoint 58 salmeterol fluticasone propionate 58 Thrombolysis 58 postintervention 58 BPH Symptom Score 58 neutrophil counts 58 -#.# log# copies mL 58 univariate analyzes 58 median PFS 58 statistical significance p 58 FACIT Fatigue 58 advanced adenomas 58 Baseline characteristics 58 Endothelial function 58 p = #.# [003] 58 X ULN 58 Postoperatively 58 p = #.# [004] 58 progression TTP 58 lymphocytosis 58 HER2 expression 58 thyroglobulin 58 Mean Symptom Complex 58 comparator arm 58 baseline serum creatinine 58 chlorambucil 58 FluCAM arm 58 interquartile range 58 glycosylated hemoglobin 58 mcg Albuferon 58 μmol L 58 Ocular Surface Disease 58 undetectable HBV DNA 58 DLQI 58 ejection fractions 58 Status Scale EDSS 58 p = NS 58 EQ 5D 58 pg mL 58 serum urate levels 58 fasting glucose levels 58 Median PFS 58 plus MTX 58 PSQI 58 Hazard Ratio HR 58 severe exacerbations 58 QRS duration 58 serum clusterin levels 58 mineral density 58 postoperative mortality 58 serum HCV RNA 58 Hazard Ratio 58 mL/min/#.# m2 58 â ‰ ¥ 58 serum prostate 58 copies mL 58 serum ALT 58 cEVR 58 receiving golimumab 58 SGOT 58 Apgar scores 58 ertapenem 58 serum aminotransferase levels 58 serum phosphate levels 58 postop 58 recurrent genital herpes 58 ADCS ADL 58 posttreatment 58 mEq L 58 intraocular inflammation 58 CIN3 58 -#.# mg dL [001] 58 IELT 58 intraobserver 58 multivariate Cox 58 mg/m2 dose 58 hsCRP levels 57 preintervention 57 ± SD 57 undetectable HCV RNA 57 dyspnea 57 BMI ≥ 57 fasting plasma glucose FPG 57 HBV DNA levels 57 advanced adenoma 57 postprocedure 57 mcg albinterferon alfa 2b 57 NNT = 57 Operative mortality 57 IU ml 57 fasting blood glucose 57 lactate dehydrogenase 57 multivariate logistic regression 57 composite endpoint 57 plasma HCV RNA 57 serum phosphorus 57 umol L 57 serum triglycerides 57 laboratory abnormalities 57 left ventricular systolic 57 triglyceride concentration 57 pulmonary exacerbations 57 CRp 57 STN stimulation 57 ipsilateral stroke 57 adenotonsillectomy 57 NIHSS score 57 PREZISTA r arm 57 subtrochanteric 57 interrater reliability 57 calculated creatinine clearance 57 urate lowering therapy 57 serum creatinine 57 clinically meaningful improvements 57 coronary artery calcification 57 Global Impression CGI 57 methacholine challenge 57 osteopenic 57 adjunctive placebo 57 NMIBC 57 nondepressed 57 hydroxyvitamin D levels 57 microalbumin test 57 asymptomatic carotid stenosis 57 CIMZIA ™ 57 flow mediated dilation 57 certolizumab 57 pg ml 57 virologic failure 57 remission CR 57 statistically significant p = 57 abdominal circumference 57 serum IGF 57 Hb A1c 57 CsA 57 Brief Pain 57 fasting glucose 57 anemia hemoglobin 57 bronchial hyperresponsiveness 57 posttransplant 57 adalimumab 57 baseline CD4 57 #OHD levels 57 mg kg dose 57 4mg/kg 57 affective psychosis 57 T2 lesions 57 GERD symptom 57 mm Hg systolic 57 CHADS 57 Hamilton Anxiety Scale 57 urinary N telopeptide 57 abdominal adiposity 57 transaminases 57 histologically confirmed 57 receiving ISENTRESS 57 serum concentrations 57 ALT flares 57 serum phosphorous 57 ANOVA 57 ug kg 57 TEAEs 57 CC genotype 57 sulfasalazine 57 systolic BP 57 adefovir treated 57 tertiles 57 arterial thromboembolic events 57 HBeAg negative patients 57 pmol L 57 CI = 57 BENICAR 57 obstructive coronary artery 57 AST ALT 57 retinal thickness 57 concomitant medications 57 tapentadol ER 57 depressive symptomatology 57 Kaplan Meier analysis 57 Secondary endpoints included 57 ß = 57 serum bilirubin 57 experienced virologic failure 57 visceral adiposity 57 evaluable subjects 57 hematologic toxicity 57 mU L 57 pericardial effusion 57 erection hardness 57 cervical intraepithelial neoplasia 57 diastolic BP 57 tirofiban 57 g dl 57 albumin excretion 57 antibody titers 56 Glasgow Coma Scale 56 ABC/3TC 56 detectable HCV RNA 56 rs# [002] 56 pT2 56 index BMI 56 ULORIC 56 residual platelet reactivity 56 Logistic regression 56 non menstrual pelvic 56 SUVmax 56 Inventory BPI 56 CFQ R 56 baseline FEV 56 ARIXTRA 56 EORTC QLQ C# 56 TPV r 56 fraction LVEF 56 TNSS 56 pulmonary arterial 56 placebo dexamethasone 56 kg m² 56 CIN2 + 56 seroprotection 56 carotid stenosis 56 LS BMD 56 aminotransferases 56 low expressors 56 fasting plasma 56 virological response 56 albuminuria 56 Stroke Scale 56 CK MB 56 arterial thickening 56 multivariable analysis 56 ATACAND 56 events MACE 56 Breslow thickness 56 seropositivity 56 periprocedural 56 Prehypertension 56 postoperative complication 56 impaired fasting glucose 56 AUCs 56 ALS Functional 56 serum triglyceride levels 56 radiographically 56 COPD exacerbation 56 haematologic 56 ZOMIG Nasal Spray 56 Visual Analog 56 Median survival 56 % CI #.#-#.# [005] 56 thyrotropin levels 56 PsA 56 mmol liter 56 ‰ ¥ 56 mm Hg diastolic 56 tipranavir ritonavir 56 nonobese 56 Apidra ® 56 8mg/kg 56 TAXUS Express Stent 56 CVD mortality 56 Incontinence Impact Questionnaire 56 piperacillin tazobactam 56 % CI #.#-#.# [002] 56 CORE OM 56 ankle brachial index 56 mg Proellex 56 #.#mmHg 56 hypophosphatemia 56 conditional logistic regression 56 mean baseline HbA1c 56 nmol liter 56 LV dysfunction 56 statistically significant p 56 SGPT 56 Hamilton Rating Scale 56 HIV RNA 56 achieved PASI 56 per deciliter mg 56 HADS 56 multivariate regression analysis 56 ropivacaine 56 #mmHg [001] 56 femoral neck 56 CIMZIA TM certolizumab pegol 56 pretest probability 56 serum parathyroid hormone 56 p ≤ 56 virologic responses 56 lymph node metastasis 56 Neuropsychiatric Inventory NPI 56 median CD4 56 SSRI SNRI 56 antihypertensive therapy 56 nonfatal myocardial infarction 56 fluticasone salmeterol 56 mmHg 56 prospectively defined 56 Stroke Scale NIHSS 56 #.#mmol L [001] 56 CR CRu 56 oral allopurinol 56 asthma exacerbation 56 node metastases 56 coronary stenosis 56 alteplase 56 Multivariate analysis 56 clinically meaningful reductions 56 HBeAg 56 leucopenia 56 HRQOL 56 BENICAR HCT 56 Insulin sensitivity 56 overt nephropathy 56 activated partial thromboplastin 56 distant metastasis 56 death reinfarction 56 Cystic Fibrosis Questionnaire Revised 56 postoperatively 56 elevated LDH 56 subclinical atherosclerosis 56 coinfected 56 HAM D# scores 56 T2 lesion volume 56 intact parathyroid hormone 56 logistic regression model 56 confirmed CCyR 56 undetectable viral load 56 diastolic hypertension 56 hs CRP 56 #mg doses [002] 56 abacavir lamivudine 56 STRIDE PD 56 TMC# r 56 -#.# ± [001] 56 grade cervical intraepithelial 55 neutrophil count 55 System IPSS 55 Free Survival PFS 55 mg dL 55 etanercept 55 Natalizumab 55 leukocytosis 55 polyarticular 55 NSTE ACS 55 HbA 1C 55 transaminase elevations 55 μg liter 55 Abnormal Involuntary Movement 55 thickness CIMT 55 febrile neutropenia 55 IQR 55 ARCOXIA 55 histologic subtype 55 eplerenone 55 subclinical hyperthyroidism 55 nonsignificant difference 55 euthymic patients 55 lispro 55 dysthymia 55 ng dl 55 % CI #.#-#.# [001] 55 interobserver reliability 55 PCA3 scores 55 maximal treadmill 55 active comparator 55 ALND 55 mcg mL 55 hypoglycemic events 55 Triglyceride levels 55 mineral density BMD 55 prospectively stratified 55 #mmHg [002] 55 inflammatory lesions 55 pulmonary capillary wedge 55 salivary cortisol 55 peak VO2 55 vertebral fracture 55 #q# deletion syndrome 55 SLNB 55 metabolic parameters 55 octreotide LAR 55 histologic 55 iPTH 55 epithelial ovarian cancer 55 severe neutropenia 55 Platelet counts 55 Severity Index 55 PCa 55 mL sec 55 leukopenia 55 tolvaptan 55 nonmetastatic prostate cancer 55 urinary albumin excretion 55 mmHg systolic 55 myocardial infarction MI 55 prostate cancer CaP 55 μg dose 55 HBeAg positive patients 55 tPSA 55 atypical ductal hyperplasia 55 BARACLUDE ® 55 nmol L 55 hepatorenal syndrome 55 hypertensives 55 polyp recurrence 55 IIIa inhibitors 55 Pred Forte 55 stent binary restenosis 55 titrated glipizide 55 DMARD 55 myeloperoxidase 55 log# IU mL 55 tolterodine ER 55 autoantibody levels 55 clodronate 55 glycaemia 55 Charlson comorbidity index 55 intraocular pressure IOP 55 Stent thrombosis 55 CSBM 55 genotypic resistance 55 ADHD RS 55 Lantus ® 55 Univariate analysis 55 salivary flow 55 echocardiographic parameters 55 low dose Iluvien 55 Folfox 55 #mg BID [003] 55 arterial oxygen saturation 55 apolipoprotein B 55 lactate dehydrogenase LDH 55 hepatic enzymes 55 SYNTAX 55 RAPAFLO R 55 chemoradiation therapy 55 insulin detemir 55 Secondary endpoints include 55 subclinical hypothyroidism 55 neurodevelopmental impairment 55 ug dose 55 FDG PET imaging 55 glycoprotein IIb IIIa inhibitors 55 SVR# 55 interferon beta therapy 55 INVEGA ® 55 hemoglobin concentrations 55 virologic response EVR 55 acetabular dysplasia 55 5-FU/LV 55 HSCT 55 apnea hypopnea 55 left ventricular LV 55 primary patency 55 QT intervals 55 mild renal insufficiency 55 hematologic parameters 55 histological subtype 55 Negative Symptoms 55 imipenem 55 Mania Rating Scale 55 bortezomib refractory 55 waist circumference WC 55 logistic regression analyzes 55 IIEF 55 dose cytarabine 55 intravaginal ejaculatory latency 55 glimepiride 55 Dyspnea 55 postmenopausal osteoporotic women 55 hsCRP 55 varices 55 Fasting blood glucose 55 radical prostatectomy RP 55 sUA levels 55 tiotropium 55 Viral load 55 spirometric 55 coronary calcification 55 prevalences 55 pelvic lymphadenectomy 55 nonresponders 55 postoperative infections 55 deep venous thromboses 55 LV ejection fraction 55 Poisson regression 55 juvenile idiopathic arthritis 55 oral antidiabetic medication 55 μg kg 55 T1a 55 #mg/dL [001] 55 microalbumin 55 somatostatin analog 55 BPRS 55 mcg doses 55 endometrial hyperplasia 55 intramuscular dose 55 neutropaenia 55 pooled comparator 55 relapsed MM 55 comorbidity 55 tocilizumab 55 nonvertebral fractures 55 serum CRP 55 achieved CCyR 55 rhinoconjunctivitis 55 lumbar spine bone 55 serum cortisol 55 postoperative pulmonary 55 lopinavir r 55 systolic blood pressures 55 gout flares 55 serum uric acid 55 serum potassium levels 55 dapagliflozin plus 55 rapid virologic response 55 Endothelial dysfunction 55 mmol L. 54 mIU ml 54 MoxDuo TM IR 54 crossclamp 54 GSTP1 54 aminotransferase ALT 54 clinically meaningful 54 endometrial carcinoma 54 hematological parameters 54 seminal vesicle invasion 54 invasive carcinomas 54 tHcy 54 #mg QD [002] 54 adjunctive ABILIFY 54 angiographically 54 mg Androxal 54 Distress Scale 54 AUC0 54 mcg kg 54 Cardiorespiratory fitness 54 Non inferiority 54 Hemoglobin A1c 54 Engerix B 54 r2 = 54 recurrent venous thromboembolism 54 Lupuzor ™ 54 transferrin saturation 54 Ki# 54 aldosterone antagonist 54 QTc 54 multivariable logistic regression 54 Ashworth Scale 54 bivalirudin monotherapy 54 severe renal impairment 54 Postoperative complications 54 elevated transaminases 54 UGT#A# * 54 receiving VICTRELIS 54 logistic regression models 54 eNO 54 CD4 + cell 54 aminotransferase levels 54 left ventricular diastolic 54 ritonavir boosted 54 mesalamine granules 54 Left Ventricular Ejection Fraction 54 mL kg 54 diastolic pressure 54 C reactive protein 54 #mg dose [002] 54 APTIVUS r 54 neurologic complications 54 sputum eosinophils 54 latent celiac disease 54 mRCC 54 ADHD Rating Scale 54 #ng/ml 54 MS DRGs 54 mU liter 54 diastolic blood pressures 54 perioperative mortality 54 neoplasias 54 test OGTT 54 serum calcium levels 54 infliximab monotherapy 54 elevated IOP 54 Visual acuity 54 absolute lymphocyte 54 covariate 54 EBRT 54 systolic hypertension 54 ng mL 54 #.#mg/dL 54 diameter stenosis 54 euthymic 54 density BMD 54 ANCOVA 54 SCr 54 CIBIC plus 54 hypoxemia 54 intraclass correlation coefficient 54 cells uL 54 serum BDNF 54 ALT elevation 54 cells mcL 54 International Prognostic Scoring 54 UACR 54 coronary artery calcium 54 R0 resection 54 generalized edema 54 #.#-#.# [011] 54 weekly CSBMs 54 aged ≥ 54 oral FTY# 54 creatinine levels 54 stage IIIb IV 54 #.#/#.# mm Hg [003] 54 plasma uric acid 54 Subgroup analyzes 54 desvenlafaxine succinate 54 cerebrovascular accident 54 pruritus itching 54 nonpregnant women 54 adrenalectomy 54 NATRECOR R 54 Doxil ® 54 CK # plasma concentrations 54 dyslipidaemia 54 gadolinium enhancing lesions 54 Depressive symptoms 54 virologic suppression 54 C Reactive Protein 54 XIENCE V vs. 54 mg Lucentis 54 mm Hg 54 covariates 54 mg ustekinumab 54 ETDRS 54 FDG uptake 54 hepatitis C genotype 54 hemoglobin A1c 54 Physical Component 54 gastric pH 54 lymphopenia 54 IL#B 54 pathologic fracture 54 uncorrected visual acuity 54 μg dL 54 abnormal cytology 54 cTnT 54 Mini Mental 54 obstructive CAD 54 airway responsiveness 54 Histologic 54 EBMT criteria 54 Cholinesterase Inhibitors 54 ejection fraction 54 Global Impression 54 prognostic variables 54 handgrip strength 54 oral vancomycin 54 ml min 54 tic severity 54 non valvular atrial 54 ARB telmisartan 54 infarct size 54 HER2 overexpression 54 normal ULN 54 Rate ORR 54 Solid Tumors 54 P ≤ 54 recurrent wheezing 54 glycemia 54 metabolic syndrome MetS 54 nodular partial response 54 ABCB1 54 rs# [004] 54 mm Stent